// App-Quantinova.ai

OC 44.4 : High plasma levels of C1 esterase inhibitor reduce intrinsic pathway-initiated coagulation and are associated with reduced future risk of venous thromboembolism

Researchers

Presenter

  • S. Grover

Principal Investigators

  • O. Snir

  • K. Hindberg

  • V. Morelli

  • H. Farkas

  • S. Jensen

  • A. Wolberg

  • T. Ueland

  • N. Mackman

  • J. Hansen

Medical Centers

  • University of North Carolina, Chapel Hill, North Carolina, United States

  • UiT – The Arctic University of Norway, Tromso, Troms, Norway

  • Thrombosis Research Center, Department of Clinical Medicine, UiT – the Arctic University of Norway, Tromsø, Troms, Norway

  • Semmelweis University, Budapest, Hungary

  • UiT – The Arctic University of Norway, Tromso, Troms, Norway

  • University of Oslo, Oslo, Norway

Locations

  • United States

  • Norway

  • Hungary

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Hereditary angioedema

  • Deep vein thrombosis

  • C1 Inhibitor Deficiency

Biomarkers

  • N/A

Drug/Treatment

  • Evithrom

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved